sc002 and Prostatic-Neoplasms

Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced prostate cancer as a mechanism of treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially developed for small cell lung cancer. We found that DLL3 is expressed in most of the castration-resistant neuroendocrine prostate cancer (CRPC-NE) (36 of 47, 76.6%) and in a subset of castration-resistant prostate adenocarcinomas (7 of 56, 12.5%). It shows minimal to no expression in localized prostate cancer (1 of 194) and benign prostate (0 of 103). DLL3 expression correlates with neuroendocrine marker expression,

Topics: Aged; Animals; Antibodies, Monoclonal, Humanized; Benzodiazepinones; Carcinoma, Neuroendocrine; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome